You eat what you are: Autophagy inhibition as a therapeutic strategy in leukemia

A. R. Sehgal, Heiko Konig, D. E. Johnson, D. Tang, R. K. Amaravadi, M. Boyiadzis, M. T. Lotze

Research output: Contribution to journalReview article

38 Citations (Scopus)

Abstract

A deeper understanding of the role of autophagy, literally 'self-eating', in normal and cancer cell biology has emerged over the last few years. Autophagy serves as a vehicle for cells to respond to various stressors including genomic, hypoxic and nutrient stress, and to oppose mechanisms of 'programmed' cell death. Here, we review not only mechanisms of cell death and cell survival but also the early successes in applying autophagy inhibition strategies in solid tumors using the only currently available clinical inhibitor, oral hydroxychloroquine. In acute leukemia, currently available chemotherapy drugs promote cell death and demonstrate clinical benefit, but relapse and subsequent chemotherapy resistance is common. Increasing preclinical data suggest that autophagy is active in leukemia as a means of promoting cell survival in response to chemotherapy. We propose coupling autophagy inhibition strategies with current cytotoxic chemotherapy and discuss synergistic combinations of available anti-leukemic therapies with autophagy inhibition. Furthermore, novel autophagy inhibitors are in development and promise to provide new therapeutic opportunities for patients with leukemia.

Original languageEnglish (US)
Pages (from-to)517-525
Number of pages9
JournalLeukemia
Volume29
Issue number3
DOIs
StatePublished - Mar 9 2015

Fingerprint

Autophagy
Leukemia
Drug Therapy
Cell Death
Therapeutics
Cell Survival
Hydroxychloroquine
Cell Biology
Neoplasms
Eating
Recurrence
Food
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Hematology
  • Cancer Research
  • Anesthesiology and Pain Medicine
  • Medicine(all)

Cite this

Sehgal, A. R., Konig, H., Johnson, D. E., Tang, D., Amaravadi, R. K., Boyiadzis, M., & Lotze, M. T. (2015). You eat what you are: Autophagy inhibition as a therapeutic strategy in leukemia. Leukemia, 29(3), 517-525. https://doi.org/10.1038/leu.2014.349

You eat what you are : Autophagy inhibition as a therapeutic strategy in leukemia. / Sehgal, A. R.; Konig, Heiko; Johnson, D. E.; Tang, D.; Amaravadi, R. K.; Boyiadzis, M.; Lotze, M. T.

In: Leukemia, Vol. 29, No. 3, 09.03.2015, p. 517-525.

Research output: Contribution to journalReview article

Sehgal, AR, Konig, H, Johnson, DE, Tang, D, Amaravadi, RK, Boyiadzis, M & Lotze, MT 2015, 'You eat what you are: Autophagy inhibition as a therapeutic strategy in leukemia', Leukemia, vol. 29, no. 3, pp. 517-525. https://doi.org/10.1038/leu.2014.349
Sehgal AR, Konig H, Johnson DE, Tang D, Amaravadi RK, Boyiadzis M et al. You eat what you are: Autophagy inhibition as a therapeutic strategy in leukemia. Leukemia. 2015 Mar 9;29(3):517-525. https://doi.org/10.1038/leu.2014.349
Sehgal, A. R. ; Konig, Heiko ; Johnson, D. E. ; Tang, D. ; Amaravadi, R. K. ; Boyiadzis, M. ; Lotze, M. T. / You eat what you are : Autophagy inhibition as a therapeutic strategy in leukemia. In: Leukemia. 2015 ; Vol. 29, No. 3. pp. 517-525.
@article{686acb01fd3c42759af8f3ea91c7408a,
title = "You eat what you are: Autophagy inhibition as a therapeutic strategy in leukemia",
abstract = "A deeper understanding of the role of autophagy, literally 'self-eating', in normal and cancer cell biology has emerged over the last few years. Autophagy serves as a vehicle for cells to respond to various stressors including genomic, hypoxic and nutrient stress, and to oppose mechanisms of 'programmed' cell death. Here, we review not only mechanisms of cell death and cell survival but also the early successes in applying autophagy inhibition strategies in solid tumors using the only currently available clinical inhibitor, oral hydroxychloroquine. In acute leukemia, currently available chemotherapy drugs promote cell death and demonstrate clinical benefit, but relapse and subsequent chemotherapy resistance is common. Increasing preclinical data suggest that autophagy is active in leukemia as a means of promoting cell survival in response to chemotherapy. We propose coupling autophagy inhibition strategies with current cytotoxic chemotherapy and discuss synergistic combinations of available anti-leukemic therapies with autophagy inhibition. Furthermore, novel autophagy inhibitors are in development and promise to provide new therapeutic opportunities for patients with leukemia.",
author = "Sehgal, {A. R.} and Heiko Konig and Johnson, {D. E.} and D. Tang and Amaravadi, {R. K.} and M. Boyiadzis and Lotze, {M. T.}",
year = "2015",
month = "3",
day = "9",
doi = "10.1038/leu.2014.349",
language = "English (US)",
volume = "29",
pages = "517--525",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - You eat what you are

T2 - Autophagy inhibition as a therapeutic strategy in leukemia

AU - Sehgal, A. R.

AU - Konig, Heiko

AU - Johnson, D. E.

AU - Tang, D.

AU - Amaravadi, R. K.

AU - Boyiadzis, M.

AU - Lotze, M. T.

PY - 2015/3/9

Y1 - 2015/3/9

N2 - A deeper understanding of the role of autophagy, literally 'self-eating', in normal and cancer cell biology has emerged over the last few years. Autophagy serves as a vehicle for cells to respond to various stressors including genomic, hypoxic and nutrient stress, and to oppose mechanisms of 'programmed' cell death. Here, we review not only mechanisms of cell death and cell survival but also the early successes in applying autophagy inhibition strategies in solid tumors using the only currently available clinical inhibitor, oral hydroxychloroquine. In acute leukemia, currently available chemotherapy drugs promote cell death and demonstrate clinical benefit, but relapse and subsequent chemotherapy resistance is common. Increasing preclinical data suggest that autophagy is active in leukemia as a means of promoting cell survival in response to chemotherapy. We propose coupling autophagy inhibition strategies with current cytotoxic chemotherapy and discuss synergistic combinations of available anti-leukemic therapies with autophagy inhibition. Furthermore, novel autophagy inhibitors are in development and promise to provide new therapeutic opportunities for patients with leukemia.

AB - A deeper understanding of the role of autophagy, literally 'self-eating', in normal and cancer cell biology has emerged over the last few years. Autophagy serves as a vehicle for cells to respond to various stressors including genomic, hypoxic and nutrient stress, and to oppose mechanisms of 'programmed' cell death. Here, we review not only mechanisms of cell death and cell survival but also the early successes in applying autophagy inhibition strategies in solid tumors using the only currently available clinical inhibitor, oral hydroxychloroquine. In acute leukemia, currently available chemotherapy drugs promote cell death and demonstrate clinical benefit, but relapse and subsequent chemotherapy resistance is common. Increasing preclinical data suggest that autophagy is active in leukemia as a means of promoting cell survival in response to chemotherapy. We propose coupling autophagy inhibition strategies with current cytotoxic chemotherapy and discuss synergistic combinations of available anti-leukemic therapies with autophagy inhibition. Furthermore, novel autophagy inhibitors are in development and promise to provide new therapeutic opportunities for patients with leukemia.

UR - http://www.scopus.com/inward/record.url?scp=84924577823&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924577823&partnerID=8YFLogxK

U2 - 10.1038/leu.2014.349

DO - 10.1038/leu.2014.349

M3 - Review article

C2 - 25541151

AN - SCOPUS:84924577823

VL - 29

SP - 517

EP - 525

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 3

ER -